STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 134998

TO: Ben Sackey **Location: 5b31/5c18** **Art Unit: 1626** **Friday, October 15, 2004** **Case Serial Number: 10/689513**	**From: Noble Jarrell** **Location: Biotech-Chem Library** **Rem 1B71** **Phone: 272-2556** **Noble.jarrell@uspto.gov**

Search Notes

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: BEN SACKEY Examiner #: 73489 Date: 10/13/04
Art Unit: 1626 Phone Number 2-0704 Serial Number: 10/689,513
Mail Box and Bldg/Room Location: _____ Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Alpha-4 Beta-amino acid hydroxyethylamino Sulfonyl urea deriv

Inventors (please provide full names): _____

Earliest Priority Filing Date: 10/30/02

**For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*



****

STAFF USE ONLY	Type of Search	Vendors and cost where applicable
Searcher: Noble	NA Sequence (#) _____	STN 263
Searcher Phone #: _____	AA Sequence (#) _____	Dialog _____
Searcher Location: _____	Structure (#) 1	Questel/Orbit _____
Date Searcher Picked Up: _____	Bibliographic _____	Dr.Link _____
Date Completed: 10/15/04	Litigation _____	Lexis/Nexis _____
Searcher Prep & Review Time: 15	Fulltext _____	Sequence Systems _____
Clerical Prep Time: _____	Patent Family _____	WWW/Internet _____
Online Time: 20	Other _____	Other (specify) _____

PTO-1590 (8-01)

=> b reg
FILE 'REGISTRY' ENTERED AT 13:16:24 ON 15 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 14 OCT 2004 HIGHEST RN 762927-58-2
DICTIONARY FILE UPDATES: 14 OCT 2004 HIGHEST RN 762927-58-2

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> d que stat l7
L5 STR



Ak—G4
@21 22

C═O
@23 24

REP G1=(0-1) AK
VAR G2=O/S/N
VAR G3=AK/21
VAR G4=CN/O/CY/23/S/26/29
NODE ATTRIBUTES:
NSPEC IS RC AT 1
NSPEC IS RC AT 29
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 14
NUMBER OF NODES IS 29

STEREO ATTRIBUTES: NONE
L7 20 SEA FILE=REGISTRY SSS FUL L5

100.0% PROCESSED 4552 ITERATIONS 20 ANSWERS
SEARCH TIME: 00.00.01

=> d his

(FILE 'HOME' ENTERED AT 12:35:25 ON 15 OCT 2004)

FILE 'HCAPLUS' ENTERED AT 12:35:55 ON 15 OCT 2004

```
L1             1 US20040171653/PN

     FILE 'REGISTRY' ENTERED AT 12:36:16 ON 15 OCT 2004

     FILE 'HCAPLUS' ENTERED AT 12:36:18 ON 15 OCT 2004
L2               TRA L1 1- RN :        49 TERMS

     FILE 'REGISTRY' ENTERED AT 12:36:18 ON 15 OCT 2004
L3            49 SEA L2

     FILE 'WPIX' ENTERED AT 12:36:24 ON 15 OCT 2004
L4             1 US20040171653/PN

     FILE 'REGISTRY' ENTERED AT 12:55:20 ON 15 OCT 2004
L5               STR
L6             0 L5
L7            20 L5 FULL
                 SAVE TEMP SAC513FUL/A L7

     FILE 'HCAPLUS' ENTERED AT 13:08:32 ON 15 OCT 2004
L8             6 L7
                 E VAZQUEZ M/AU
L9           720 E3,E21-23
                 E VAZQUEX MICHAEL/AU
                 E VAZQUEZ MICHAEL/AU
L10           50 E3,E5-7
                 E MUELLER R/AU
L11          858 E3-4
                 E MUELLER RICHARD/AU
L12          340 E3-7
                 E TALLEY J/AU
L13          136 E3,E7,E24-25
                 E GETMAN D/AU
L14          108 E3,E5,E10-12
                 E DECRESCENZO G/AU
L15           69 E3-6
                 E SUN E/AU
L16           17 E3,E8-9
                 E SUN ERIC/AU
L17           34 E3-7
L18        27165 (SEARLE OR MONSANTO)/CS,PA

     FILE 'HCAOLD' ENTERED AT 13:12:59 ON 15 OCT 2004
L19            0 L7

     FILE 'HCAPLUS' ENTERED AT 13:13:04 ON 15 OCT 2004
L20            2 L8 AND L9-17
L21            3 L8 AND L18
L22            1 L21 NOT L20
L23            4 L8 NOT L20
L24            3 L23 AND (PY<=1992 OR PRY<=1992 OR AY<=1992 OR PD<19921030 OR AD

=> b hcap
FILE 'HCAPLUS' ENTERED AT 13:16:36 ON 15 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
```


FILE COVERS 1907 - 15 Oct 2004 VOL 141 ISS 17
FILE LAST UPDATED: 14 Oct 2004 (20041014/ED)

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d all hitstr 120 tot

L20 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1996:725344 HCAPLUS
DN 126:75247
ED Entered STN: 11 Dec 1996
TI Preparation of .alpha.- and .beta.-amino acid hydroxyethylamino sulfonyl urea derivatives as retroviral protease inhibitors
IN **Vazquez, Michael L.; Mueller, Richard A.; Talley, John J.; Getman, Daniel P.; Decrescenzo, Gary A.; Sun, Eric T.**
PA G.D. Searle and Co., USA
SO U.S., 37 pp.
CODEN: USXXAM
DT Patent
LA English
IC ICM C07D401-12
ICS C07D413-12; C07D417-12; A61K031-47; A61K031-505; A61K031-54
NCL 514314000
CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1, 7, 63
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5578606	A	19961126	US 1992-968712	19921030
	US 6022872	A	20000208	US 1996-709069	19960906
	US 6211176	B1	20010403	US 1999-345739	19990701
	US 6403585	B1	20020611	US 2000-731911	20001208
	US 2003144342	A1	20030731	US 2002-138534	20020506
	US 6683648	B2	20040127		
	US 2004171653	A1	20040902	US 2003-689513	20031021
PRAI	US 1992-968712	A3	19921030		
	US 1996-709069	A1	19960906		
	US 1999-345739	A1	19990701		
	US 2000-731911	A1	20001208		
	US 2002-138534	A1	20020506		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 5578606	ICM	C07D401-12
	ICS	C07D413-12; C07D417-12; A61K031-47; A61K031-505; A61K031-54
	NCL	514314000
US 5578606	ECLA	C07C307/06; C07D239/38; C07D307/85; C07K005/06A1A1; C07K005/06A1A3; C07K005/06H2; C07K005/06T; C07D023/42C; C07D215/48; C07D215/50; C07D215/54; C07D235/06B
US 6403585	ECLA	C07C307/06; C07D213/42C; C07D215/48; C07D215/50; C07D215/54; C07D235/06B; C07D239/38; C07D030/85; C07K005/06A1A3; C07K005/06A1A1; C07K005/06H2; C07K005/06T
US 2003144342	ECLA	C07C307/06; C07D213/42C; C07D215/48; C07D215/50; C07D215/54; C07D235/06B; C07D239/38; C07D030/85; C07K005/06A1A3; C07K005/06A1A1; C07K005/06H2; C07K005/06T

OS MARPAT 126:75247
GI



I



II



III

Searched by Noble Jarrell

AB .alpha.- And .beta.-amino acid hydroxyethylamino sulfonyl urea derivative compds., e.g. I [R3 = C1-8 alkyl, (un)substituted C1-8 alkylphenyl, C1-8 heteroaralkyl; R8 = (un)substituted Ph, heterocyclyl, CN, OH, CO2H, C1-8 alkylthio, (un)substituted phenylsulfonyl, C1-8 alkanoyl, C1-8 alkoxycarbonyl, C1-8 dialkylaminocarbonyl, N-C1-8- alkyl-N-phenylcarbamoyl, 2-heterocyclylethoxy, heterocyclyl; n = 0-2], are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. Thus, coupling of protected amino(hydroxy)phenylbutylamine II (Z = PhCH2O2C) (prepared in 3 steps from chloromethyl ketone Z-L-Phe-CH2Cl) with ClSO2NHCMe2CO2Me, followed by hydrogenolysis and coupling with Z-Asn-OH gave inhibitor III.

ST retroviral protease inhibitor hydroxyethylaminosulfonyl urea peptide; protease inhibitor hydroxyethylaminosulfonyl urea peptide prepn; HIV virucide hydroxyethylaminosulfonyl urea peptide prepn

IT Antiviral agents
Human immunodeficiency virus 1
(preparation of hydroxyethylamino sulfonyl urea peptide derivs. as retroviral protease inhibitors)

IT **185256-67-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hydroxyethylamino sulfonyl urea peptide derivs. as retroviral protease inhibitors)

IT 63-91-2, L-Phenylalanine, reactions 78-81-9, Isobutylamine 105-13-5, 4-Methoxybenzyl alcohol 107-85-7, Isoamylamine 2170-03-8 2304-96-3 26049-94-5 152714-71-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of hydroxyethylamino sulfonyl urea peptide derivs. as retroviral protease inhibitors)

IT 107-95-9P, .beta.-Alanine 498-25-9P 541-48-0P, 3-Aminobutanoic acid 3377-31-9P 3653-34-7P 4385-92-6P 5699-54-7P 15099-85-1P 16934-21-7P 32723-74-3P 32723-76-5P 53874-24-1P 60427-77-2P 65414-77-9P 75081-40-2P 83509-04-0P 91247-38-0P 95598-13-3P 100869-07-6P 111060-52-7P 111060-64-1P 127927-43-9P 128018-43-9P 128018-44-0P 130165-86-5P 132605-93-7P 132605-97-1P 132605-98-2P 132696-45-8P 143224-62-8P 143224-86-6P 143225-04-1P 160191-57-1P 185256-61-5P 185256-62-6P 185256-63-7P 185256-64-8P 185256-65-9P 185256-66-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of hydroxyethylamino sulfonyl urea peptide derivs. as retroviral protease inhibitors)

IT 9001-92-7, Protease
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(retroviral; preparation of hydroxyethylamino sulfonyl urea peptide derivs. as retroviral protease inhibitors)

IT **185256-67-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hydroxyethylamino sulfonyl urea peptide derivs. as retroviral protease inhibitors)

RN 185256-67-1 HCAPLUS

CN 10-Thia-2,5,9,11-tetraazatridecanedioic acid, 3-(2-amino-2-oxoethyl)-7-hydroxy-12,12-dimethyl-9-(2-methylpropyl)-4-oxo-6-(phenylmethyl)-, 13-methyl 1-(phenylmethyl) ester, 10,10-dioxide, [3S-(3R*,6R*,7S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1995:330514 HCAPLUS
DN 122:106521
ED Entered STN: 04 Feb 1995
TI Preparation of N-sulfamidohydroxyalkyl amino acid amides as retroviral protease inhibitors
IN **Vazquez, Michael L.; Mueller, Richard A.; Talley, John J.; Getman, Daniel P.; Decrescenzo, Gary A.; Sun, Eric T.**
PA G.D. Searle and Co., USA; Monsanto Co.
SO PCT Int. Appl., 153 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07C307-06
ICS C07D295-22; C07K005-06; C07D215-48; A61K031-18; A61K031-495; A61K031-45; A61K031-40; A61K037-02
CC 34-2 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9410134	A1	19940511	WO 1993-US10552	19931029
	W: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2142997	AA	19940511	CA 1993-2142997	19931029
	AU 9455470	A1	19940524	AU 1994-55470	19931029
	EP 666842	A1	19950816	EP 1994-900506	19931029
	EP 666842	B1	19980624		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	EP 810208	A2	19971203	EP 1997-113206	19931029
	EP 810208	A3	19981202		
	EP 810208	B1	20020102		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
	AT 167669	E	19980715	AT 1994-900506	19931029
	ES 2118364	T3	19980916	ES 1994-900506	19931029
	AT 211462	E	20020115	AT 1997-113206	19931029
	PT 810208	T	20020628	PT 1997-113206	19931029
	ES 2170305	T3	20020801	ES 1997-113206	19931029
	US 6156768	A	20001205	US 1995-379545	19950202
	US 6444678	B1	20020903	US 2000-633063	20000804
	US 2003158236	A1	20030821	US 2002-178956	20020625
PRAI	US 1992-968730	A	19921030		
	EP 1994-900506	A3	19931029		
	WO 1993-US10552	W	19931029		
	US 1995-379545	A3	19950202		
	US 2000-633063	A1	20000804		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9410134	ICM	C07C307-06
	ICS	C07D295-22; C07K005-06; C07D215-48; A61K031-18; A61K031-495; A61K031-45; A61K031-40; A61K037-02
US 6444678	ECLA	C07C307/06; C07D215/48; C07D295/22C2; C07K005/06A1A1;

C07K005/06H2
US 2003158236 ECLA C07C307/06; C07D215/48; C07D295/22C2; C07K005/06A1A1; C07K005/06H2
OS MARPAT 122:106521
GI



AB RR'N(CR7R8)tCHR1C(:Y)NR6CHR2CH(OH)CH2NR3SOxNR4R5 [R = H, (cyclo)alkyl, (hetero)aryl, alkyl(oxy)carbonyl, heterocyclyl(oxy)carbonyl, etc.; R' = groups cited for R3, R''SO2; R'' = groups cited for R3; NRR' = heterocyclyl, heteroaryl; R1,R7,R8 = H, (halo)alkyl, amino acid side chain, CONH2, CO2Me, etc.; R1R7 = atoms to form a cycloalkyl group; R2 = (un)substituted (cyclo)alkyl, aryl(alkyl); R3 = (cyclo)alkyl, (hetero)aryl(alkyl), aminoalkyl, etc.; R4,R5 = H, groups cited for R3; NR4R5 = heterocyclyl, heteroaryl; R6 = H, alkyl; Y = O, S, NH, NR3; t = 0-2; x = 1 or 2] were prepared Thus, N-benzyloxycarbonyl-3(S)-amino-1,2(S)-epoxy-4-phenylbutane (preparation given) was condensed with Me2CHCH2NH2 and the product amidated by ClSO2NHCMe3 (preparation given) to give, after deprotection, sulfamamide I (R10 = H) which was N-acylated by N-BOC-L-asparagine and the deprotected product N-acylated by quinoline-2-carboxylic acid to give I (R10 = quinolinoylasparaginyl group Q). The latter had IC50 of 2nM against HIV-1 infection of CEM cells in vitro.

ST amino acid amide sulfamidohydroxyalkyl antiviral; retroviral protease inhibitor amino acid

IT Acquired immune deficiency syndrome
(treatment of, N-sulfamidohydroxyalkyl amino acid amides for)

IT Virus, animal
(human immunodeficiency 1, infection by, treatment of, N-sulfamidohydroxyalkyl amino acid amides for)

IT Virus, animal
(retro-, protease of, inhibition of, N-sulfamidohydroxyalkyl amino acid amides for)

IT 7338-27-4P 10305-43-8P, Butylsulfamoyl chloride 33581-95-2P, tert-Butylsulfamoyl chloride 33581-96-3P 39085-61-5P, Butylsulfamic acid 60427-77-2P, 4-(4-Methoxybenzyl) itaconate 83509-04-0P 95437-43-7P 111060-52-7P 111060-64-1P 127927-43-9P 128018-43-9P 128018-44-0P 130165-86-5P 132605-93-7P 132605-97-1P 132605-98-2P 132696-45-8P 143224-48-0P 143224-62-8P 143224-86-6P 143225-04-1P 143244-71-7P 143576-90-3P 160676-95-9P 160676-96-0P 160676-97-1P 160676-98-2P 160676-99-3P 160677-00-9P 160677-01-0P 160677-02-1P 160677-03-2P 160677-04-3P 160677-05-4P 160677-06-5P **160677-07-6P** **160677-08-7P** 160677-09-8P 160677-10-1P **160677-11-2P** 160677-12-3P **160677-13-4P** **160677-14-5P** **160677-15-6P** 160677-20-3P 160677-21-4P 160677-22-5P 160677-23-6P 160677-24-7P 160677-25-8P 160677-26-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of retroviral protease inhibitor)

IT **160676-88-0P** **160676-89-1P** 160676-90-4P **160676-91-5P** **160676-92-6P** 160676-93-7P 160676-94-8P **160677-16-7P** **160677-17-8P** **160677-18-9P** **160677-27-0P** **160677-28-1P** 160677-29-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of, as retroviral protease inhibitor)

IT 63-91-2, L-Phenylalanine, reactions 75-65-0, tert-Butanol, reactions 78-81-9, Isobutylamine 100-39-0, Benzyl bromide 105-13-5, 4-Methoxybenzyl alcohol 107-85-7, Isoamylamine 111-36-4, Butylisocyanate 2170-03-8, Itaconic anhydride 7536-55-2 26049-94-5, N-Benzyloxycarbonyl-L-phenylalanine chloromethyl ketone 35856-62-3, 1-ChlorosulfonylPiperidine 50398-09-9, 1-Methylpiperazine hydrochloride 62965-10-0 136465-99-1, 2-Quinolinecarboxylic acid N-hydroxysuccinimide ester 160677-19-0

RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of retroviral protease inhibitor)

IT **160677-07-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of retroviral protease inhibitor)

RN 160677-07-6 HCAPLUS

CN 10-Thia-2,5,9,11-tetraazapentadecanoic acid, 3-(1,1-dimethylethyl)-7-hydroxy-9-(2-methylpropyl)-4-oxo-6-(phenylmethyl)-, phenylmethyl ester, 10,10-dioxide, [3S-(3R*,6R*,7S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d all fhitstr l22 tot

L22 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 1996:153437 HCAPLUS

DN 124:220480

ED Entered STN: 16 Mar 1996

TI Retroviral protease inhibitor combinations

IN Bryant, Martin L.; Potts, Karen E.; Smidt, Mary; Tucker, Simon P.

PA G.D. Searle and Co., USA

SO PCT Int. Appl., 64 pp.
CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K031-425
ICS A61K031-495; A61K031-16; A61K031-44; A61K031-18; A61K031-395

CC 1-5 (Pharmacology)
Section cross-reference(s): 28, 34

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9533464	A2	19951214	WO 1995-US6673	19950602
	WO 9533464	A3	19960104		
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2191948	AA	19951214	CA 1995-2191948	19950602
	AU 9526510	A1	19960104	AU 1995-26510	19950602
	AU 696299	B2	19980903		
	EP 762880	A1	19970319	EP 1995-921428	19950602
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	BR 9507912	A	19970812	BR 1995-7912	19950602
	CN 1166786	A	19971203	CN 1995-194464	19950602
	HU 76979	A2	19980128	HU 1996-3328	19950602
	JP 10505324	T2	19980526	JP 1995-501057	19950602
	NZ 287702	A	20000623	NZ 1995-287702	19950602
	US 6100277	A	20000808	US 1995-458154	19950602
	PL 180070	B1	20001229	PL 1995-317425	19950602
	RU 2166317	C2	20010510	RU 1997-100123	19950602
	NO 9605136	A	19970120	NO 1996-5136	19961202
	FI 9604835	A	19970129	FI 1996-4835	19961203
	US 2003207813	A1	20031106	US 2002-253899	20020925
PRAI	US 1994-253638	A2	19940603		
	WO 1995-US6673	W	19950602		

US 1996-737960 B1 19961209

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9533464	ICM	A61K031-425
	ICS	A61K031-495; A61K031-16; A61K031-44; A61K031-18; A61K031-395

AB A method is disclosed for the treatment of mammalian retrovirus infections, e.g. HIV, using combinations of retroviral protease inhibitors which are effective in preventing the replication of the retroviruses in vitro or in vivo. In particular, the invention provides protease inhibitor compds. used in combination therapy with other protease inhibitor compds. Also disclosed is combination therapy with a combination of protease inhibitors and antiviral agents other than protease inhibitors. Preparation and activity of selected inhibitors is included.

ST retrovirus protease inhibitor combination; virucide retrovirus protease inhibitor prepn

IT Drug resistance
Felis catus
Monkey
Virucides and Virustats
(retroviral protease inhibitor combinations, and protease inhibitor preparation)

IT Nucleosides, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(analogs, retroviral protease inhibitor combinations, and protease inhibitor preparation)

IT Ribonucleic acid formation factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(gene tat, antagonists; retroviral protease inhibitor combinations, and protease inhibitor preparation)

IT Virus, animal
(human T-cell leukemia, retroviral protease inhibitor combinations, and protease inhibitor preparation)

IT Virus, animal
(human immunodeficiency, retroviral protease inhibitor combinations, and protease inhibitor preparation)

IT Virus, animal
(human immunodeficiency 1, retroviral protease inhibitor combinations, and protease inhibitor preparation)

IT Virus, animal
(human immunodeficiency 2, retroviral protease inhibitor combinations, and protease inhibitor preparation)

IT Virus, animal
(retro-, retroviral protease inhibitor combinations, and protease inhibitor preparation)

IT 144114-21-6, Retropepsin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; protease inhibitor combinations against HIV, and protease inhibitor preparation)

IT 9032-92-2, Glycosidase 9068-38-6, Reverse transcriptase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; retroviral protease inhibitor combinations, and protease inhibitor preparation)

IT 143224-34-4 143224-35-5 159005-88-6 **160676-92-6**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(retroviral protease inhibitor combinations, and protease inhibitor preparation)

IT 174303-65-2P 174303-66-3P 174303-67-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(retroviral protease inhibitor combinations, and protease inhibitor preparation)

IT 127779-20-8 155213-67-5, A 84538 157566-81-9 157810-81-6, L 735524 159910-86-8 159989-65-8, AG 1343 174391-92-5
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(retroviral protease inhibitor combinations, and protease inhibitor preparation)

IT 63-91-2, L-Phenylalanine, reactions 78-81-9, Isobutylamine 100-39-0, Benzyl bromide 123-75-1, Pyrrolidine, reactions 144-62-7, Oxalic acid, reactions 274-09-9, 1,3-Benzodioxole 541-88-8, Chloroacetic anhydride

3182-95-4, L-Phenylalaninol 75172-11-1 169331-42-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(retroviral protease inhibitor combinations, and protease inhibitor preparation)

IT 111060-52-7P 111060-64-1P 111138-83-1P 115010-10-1P, 1,3-Benzodioxole-5-sulfonyl chloride 127927-43-9P 143291-14-9P 174303-68-5P 174303-69-6P 174303-70-9P 174303-71-0P 174391-93-6P 174799-02-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(retroviral protease inhibitor combinations, and protease inhibitor preparation)

IT 7481-89-2, DDC 30516-87-1, AZT 69655-05-6, DDI 72599-27-0, N-Butyl-1-deoxynojirimycin 79831-76-8, Castanospermine 134878-17-4, A 77003 161814-49-9, VX 478
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(retroviral protease inhibitor combinations, and protease inhibitor preparation)

IT 9001-92-7, Protease
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(retroviral, inhibitors; retroviral protease inhibitor combinations, and protease inhibitor preparation)

IT **160676-92-6**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(retroviral protease inhibitor combinations, and protease inhibitor preparation)

RN 160676-92-6 HCAPLUS
CN Butanediamide, N1-[3-[[[(1,1-dimethylethyl)amino]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, [1S-[1R*(R*),2S*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d all hitstr 124 tot

L24 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:502547 HCAPLUS
DN 129:136097
ED Entered STN: 13 Aug 1998
TI Preparation of heterocyclic sulfonamide inhibitors of aspartyl protease
IN Tung, Roger D.; Murcko, Mark A.; Bhisetti, Govinda Rao
PA Vertex Pharmaceuticals, Incorporated, USA
SO U.S., 87 pp., Cont.-in-part of U.S. 5,585,397.
CODEN: USXXAM
DT Patent
LA English
IC ICM C07D215-12
NCL 546169000
CC 27-16 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1, 28
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5783701	A	19980721	US 1995-393460	19950223 <--
	EP 885887	A2	19981223	EP 1998-113921	19930907 <--
	EP 885887	A3	19990203		
	EP 885887	B1	20030528		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
	US 5585397	A	19961217	US 1993-142327	19931124 <--

US 5723490	A	19980303	US 1995-424819	19950419 <--
US 5977137	A	19991102	US 1998-115394	19980714 <--
US 6392046	B1	20020521	US 1999-409808	19990930 <--
US 2003064977	A1	20030403	US 2002-94763	20020308 <--
US 6720335	B2	20040413		
US 2004167116	A1	20040826	US 2004-786997	20040224 <--
DRAI US 1992 941982	B2	19920908 <--		
US 1993-142327	A2	19931124		
EP 1993-921428	A3	19930907		
WO 1993-US8458	W	19930907		
US 1995-393460	B2	19950223		
US 1998-115394	A3	19980714		
US 1999-409808	A3	19990930		
US 2002-94763	A1	20020308		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 5783701	ICM	C07D215-12
	NCL	546169000
US 5783701	ECLA	C07D207/26C; C07D413/12; C07D413/12; C07D413/14; C07D413/14; C07D417/12; C07K005/06H2; C07D209/08; C07D213/30D; C07D215/48; C07D231/14; C07D263/24; C07D271/08; C07D277/36; C07D307/12; C07D307/20; C07D403/12; C07D405/12; C07D405/12; C07D409/12; C07D409/12; C07D409/14; C07D413/12; C07D413/12 <--
US 5585397	ECLA	C07D207/26C; C07D209/08; C07D213/30D; C07D215/48; C07D231/14; C07D239/22D2; C07D263/24; C07D271/08; C07D277/36; C07D307/12; C07D307/20; C07D403/12; C07D405/12; C07D405/12; C07D409/12; C07D409/12; C07D409/14; C07D413/12; C07D413/12; C07D413/12; C07D413/12; C07D413/14; C07D413/14; C07D417/12; C07K005/06H2 <--
US 5977137	ECLA	C07K005/06H2 <--
US 6392046	ECLA	C07D207/26C; C07D213/30D; C07D215/48; C07D209/08; C07D231/14; C07D239/22D2; C07D263/24; C07D071/08; C07D277/36; C07D307/12; C07D307/20; C07D403/12; C07D405/12; C07D405/2; C07D405/12; C07D409/12; C07D409/12; C07D409/14; C07D413/12; C07D413/12; C07D413/12; C07D413/12; C07D413/14; C07D413/14; C07D417/12; C07K005/06H2 <--
US 2003064977	ECLA	C07D207/26C; C07D209/08; C07D213/30D; C07D215/48; C07D231/14; C07D239/22D2; C07D263/24; C07D071/08; C07D277/36; C07D307/12; C07D307/20; C07D403/12; C07D405/12; C07D405/2; C07D405/12; C07D409/12; C07D409/12; C07D409/14; C07D413/12; C07D413/12; C07D413/12; C07D413/12; C07D413/14; C07D413/14; C07D417/12; C07K005/06H2 <--

OS MARPAT 129:136097

GI



I



II

AB The title compds. I [A = H, -Ht, -R1Ht, (un)substituted -R1-alk(en)yl; R1 = CO, SO2, COCO, OCO, OSO2, NR2SO2, NR2CO, NR2COCO; Ht = (un)substituted cycloalk(en)yl, aryl, (benzo)heterocyclyl; R2 = H, alkyl, -alkyl-R7; B = NR2C(R3)2CO; n = 0, 1; R3 = (un)substituted alk(en)yl or cycloalk(en)yl; n = 1, 2; D, D' = R7, (un)substituted alk(en)yl or cycloalk(en)yl; R7 = (un)substituted Ph, carbocyclyl, or heterocyclyl; E = Ht, -O-Ht, -Ht-Ht, OR3, NR2R3, (un)substituted alk(en)yl or carbocyclyl; R4 = OR2, CONHR2,

SO2NHR2, halo, NR2COR2, cyano] are prepared as inhibitors of HIV aspartyl protease. The invention also relates to pharmaceutical compns. comprising these compds. The compds. and pharmaceutical compns. are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity. The invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the invention compds., and to methods for screening compds. for anti-HIV activity. Prepns. of almost 200 compds. are described, and some of these plus addnl. compds. are claimed. Some of the compds., e.g., II, inhibit HIV replication (IC90) in CCRM-CEM cells in vitro at concns. of .ltoreq. 100 nM.

ST sulfonamide prepn aspartyl protease inhibitor; HIV antiviral sulfonamide prepn

IT Antiviral agents
Human T-lymphotropic virus
Human immunodeficiency virus 1
Human immunodeficiency virus 2
(preparation of heterocyclic sulfonamide derivs. as inhibitors of HIV aspartyl protease)

IT 144114-21-6, Retropepsin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; preparation of heterocyclic sulfonamide derivs. as inhibitors of HIV aspartyl protease)

IT 1080-11-1P 1828-66-6P, 4-Morpholinesulfonyl chloride 4295-99-2P
6053-81-2P, Aminomethylcyclopentane 23905-46-6P 25506-37-0P
30293-86-8P 32939-32-5P 35856-62-3P, 1-Piperidinesulfonyl chloride
52206-05-0P 52665-49-3P, 3-Furansulfonyl chloride 54981-39-4P
87001-32-9P, 4-Benzyloxybenzenesulfonyl chloride 102522-17-8P
114322-14-4P, 2,1,3-Benzoxadiazole-4-sulfonyl chloride 115010-10-1P,
1,3-Benzodioxole-5-sulfonyl chloride 115010-11-2P, 2,3-Dihydrobenzofuran-5-sulfonyl chloride 116586-32-4P 130290-79-8P 132682-22-5P
132682-23-6P 134807-06-0P 134807-20-8P 138499-08-8P 143224-83-3P
158851-95-7P 159006-03-8P 159006-20-9P 159141-66-9P 160231-97-0P
160231-98-1P 160231-99-2P 160232-00-8P 160232-01-9P 160232-02-0P
160232-03-1P 160232-05-3P 160232-06-4P 160232-08-6P 160232-09-7P
160232-10-0P 160232-11-1P 160232-12-2P 160232-13-3P 160232-14-4P
160232-15-5P, 2,1,3-Benzoxadiazole-4-sulfonic acid 160232-17-7P
160232-18-8P 160232-19-9P, 2,1,3-Benzoxadiazole-5-thiol 160232-20-2P,
2,1,3-Benzoxadiazole-5-sulfonyl chloride 160232-22-4P 160232-23-5P
160232-24-6P 160232-25-7P 160232-26-8P 160232-27-9P 160232-28-0P
160232-29-1P 160232-30-4P 160232-31-5P 160232-32-6P 160232-33-7P
160232-34-8P 160232-36-0P 160232-37-1P 160232-38-2P 160232-39-3P
160232-40-6P 160232-41-7P 160232-42-8P 160232-43-9P 160232-44-0P
160232-45-1P 160232-46-2P 160232-47-3P 160232-48-4P 160232-49-5P
160232-50-8P 160232-51-9P 160232-52-0P 160232-53-1P 160232-54-2P
160232-56-4P 160232-60-0P 160232-61-1P 160232-62-2P 160232-63-3P
160232-64-4P 160232-65-5P 160232-66-6P 160232-68-8P 160232-69-9P
160232-70-2P 160232-71-3P 160232-72-4P 160232-73-5P 160232-74-6P
160232-75-7P 160232-76-8P 160232-77-9P 160232-78-0P 160232-79-1P
160232-80-4P 160232-81-5P 160232-82-6P 160232-83-7P 160232-84-8P
160232-85-9P 160232-86-0P 160232-87-1P 160232-89-3P 160232-91-7P
160232-92-8P 160232-93-9P 160232-94-0P 160232-95-1P 160232-96-2P
160232-97-3P 160232-98-4P 160232-99-5P 160233-00-1P 160233-01-2P
160233-02-3P 160233-03-4P 160233-04-5P 160233-05-6P 160233-06-7P
160233-07-8P 160233-08-9P 160233-09-0P 160233-12-5P 160233-13-6P
160233-19-2P 160233-21-6P 160233-22-7P 160233-23-8P 160233-24-9P
160233-31-8P 160333-46-0P 160333-47-1P 160333-49-3P 160333-50-6P
184357-14-0P 184357-17-3P 186463-21-8P 186463-22-9P 186463-23-0P
186463-24-1P 186463-25-2P 186463-26-3P 186463-27-4P 186463-28-5P
186463-29-6P 186463-30-9P 186463-31-0P 186463-32-1P 186463-33-2P
186463-35-4P 186463-37-6P 186463-39-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of heterocyclic sulfonamide derivs. as inhibitors of HIV aspartyl protease)

IT 157567-04-9P 157567-10-7P 159005-79-5P 159005-82-0P 159005-86-4P
160230-05-7P 160230-06-8P 160230-07-9P 160230-08-0P 160230-09-1P
160230-10-4P 160230-11-5P 160230-12-6P 160230-13-7P 160230-14-8P
160230-15-9P 160230-16-0P 160230-17-1P 160230-18-2P
160230-19-3P 160230-20-6P 160230-21-7P 160230-22-8P 160230-23-9P
160230-24-0P 160230-25-1P 160230-27-3P 160230-29-5P
160230-31-9P 160230-33-1P 160230-35-3P 160230-36-4P
160230-37-5P 160230-38-6P 160230-39-7P 160230-40-0P 160230-41-1P
160230-42-2P 160230-43-3P 160230-44-4P 160230-45-5P 160230-46-6P
160230-47-7P 160230-48-8P 160230-49-9P 160230-50-2P 160230-51-3P
160230-52-4P 160230-53-5P 160230-54-6P 160230-55-7P 160230-56-8P
160230-57-9P 160230-58-0P 160230-59-1P 160230-60-4P 160230-61-5P

160230-62-6P 160230-63-7P 160230-64-8P 160230-65-9P 160230-66-0P
160230-67-1P 160230-68-2P 160230-69-3P 160230-70-6P 160230-71-7P
160230-72-8P 160230-73-9P 160230-74-0P 160230-75-1P 160230-76-2P
160230-77-3P 160230-78-4P 160230-79-5P 160230-80-8P 160230-81-9P
160230-82-0P 160230-83-1P 160230-84-2P 160230-85-3P 160230-86-4P
160230-87-5P 160230-88-6P 160230-89-7P 160230-91-1P 160230-92-2P
160230-93-3P 160230-94-4P 160230-95-5P 160230-97-7P 160230-98-8P
160231-00-5P 160231-01-6P 160231-02-7P 160231-03-8P 160231-04-9P
160231-05-0P 160231-06-1P 160231-07-2P 160231-08-3P 160231-10-7P
160231-11-8P 160231-12-9P 160231-13-0P 160231-14-1P 160231-15-2P
160231-16-3P 160231-17-4P 160231-18-5P 160231-19-6P 160231-20-9P
160231-21-0P 160231-22-1P 160231-23-2P 160231-24-3P 160231-25-4P
160231-26-5P 160231-27-6P 160231-28-7P 160231-29-8P 160231-30-1P
160231-32-3P 160231-33-4P 160231-36-7P 160231-37-8P 160231-38-9P
160231-39-0P 160231-40-3P 160231-41-4P 160231-42-5P 160231-43-6P
160231-44-7P 160231-45-8P 160231-46-9P 160231-47-0P 160231-48-1P
160231-49-2P 160231-51-6P 160231-52-7P 160231-53-8P 160231-54-9P
160231-55-0P 160231-56-1P 160231-57-2P 160231-58-3P 160231-59-4P
160231-60-7P 160231-61-8P 160231-62-9P 160231-63-0P 160231-64-1P
160231-65-2P 160231-66-3P 160231-67-4P 160231-68-5P 160231-69-6P
160231-71-0P 160231-72-1P 160231-73-2P 160231-74-3P 160231-75-4P
160231-76-5P 160231-77-6P 160231-78-7P 160231-79-8P 160231-80-1P
160231-81-2P 160231-82-3P 160231-83-4P 160231-84-5P 160231-85-6P
160231-86-7P 160231-87-8P 160231-88-9P 160231-89-0P 160231-90-3P
160231-91-4P 160231-92-5P 160231-93-6P 160231-95-8P 160231-96-9P
160333-38-0P 160333-40-4P 160333-41-5P 160333-42-6P 160333-43-7P
160333-44-8P 160333-45-9P 161814-49-9P 186462-96-4P 186463-14-9P
186463-15-0P 186463-16-1P 186463-17-2P 186463-18-3P 186463-19-4P
186463-20-7P 186464-71-1P 203851-75-6P 203851-81-4P 203851-83-6P
203851-85-8P 203851-86-9P 210537-81-8P 210537-82-9P 210537-83-0P
210537-84-1P 210537-85-2P 210537-86-3P 210537-87-4P 210537-88-5P
210537-89-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic sulfonamide derivs. as inhibitors of HIV aspartyl protease)

IT 78169-47-8, Aspartyl protease
RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)
(preparation of heterocyclic sulfonamide derivs. as inhibitors of HIV aspartyl protease)

IT 60-12-8, Phenethyl alcohol 74-89-5, Methylamine, reactions 75-44-5, Carbonic dichloride 78-81-9, Isobutylamine 79-22-1, Methyl chloroformate 93-10-7, Quinaldic acid 98-09-9, Benzenesulfonyl chloride 98-31-7, 3,4-Dichlorobenzenesulfonyl chloride 98-59-9, p-Toluenesulfonyl chloride 98-68-0, 4-Methoxybenzenesulfonyl chloride 98-74-8, p-Nitrobenzenesulfonyl chloride 98-79-3, L-Pyroglutamic acid 99-16-1 100-46-9, Benzylamine, reactions 100-55-0, 3-Pyridylcarbinol 105-13-5, 4-Methoxybenzyl alcohol 108-23-6, Isopropyl chloroformate 109-61-5, Propyl chloroformate 110-89-4, Piperidine, reactions 110-91-8, Morpholine, reactions 121-47-1, 3-Aminobenzenesulfonic acid 121-60-8, 4-Acetamidobenzenesulfonyl chloride 124-63-0, Methanesulfonyl chloride 274-09-9, 1,3-Benzodioxole 349-71-3, 3-Fluoro-4-acetamidobenzenesulfonyl chloride 453-20-3 496-16-2, 2,3-Dihydrobenzofuran 501-53-1, Benzyl chloroformate 541-41-3, Ethyl chloroformate 543-27-1, Isobutyl chloroformate 585-47-7, 1,3-Benzenedisulfonyl dichloride 586-98-1, 2-Pyridylcarbinol 612-16-8, 2-Methoxybenzyl alcohol 617-89-0, Furfurylamine 628-12-6, 2-Methoxyethyl chloroformate 638-32-4, Succinamic acid 701-99-5, Phenoxyacetyl chloride 768-09-2, 2,1,3-Benzoxadiazol-5-ol 777-44-6, 3-Trifluoromethylbenzenesulfonyl chloride 1003-03-8, Cyclopentylamine 1445-91-6, (s)-(-)-1-Phenylethanol 1483-28-9, 2,5-Dimethoxybenzenesulfonyl chloride 1517-69-7, (+)-1-Phenylethanol 1656-44-6, 2,4-Dinitrobenzenesulfonyl chloride 1885-14-9, Phenyl chloroformate 1939-99-7, .alpha.-Toluenesulfonyl chloride 2905-21-7, 2-Fluorobenzenesulfonyl chloride 2937-50-0, Allyl chloroformate 2942-58-7, Diethyl cyanophosphonate 3160-59-6 3173-56-6, Benzyl isocyanate 3218-02-8, Cyclohexanemethanamine 3445-11-2 3513-81-3, 2-Methylene-1,3-propanediol 4025-64-3 4254-02-8, Cyclopentanecarbonitrile 4319-49-7, N-Aminomorpholine 5070-13-3 5680-80-8, Serine methyl ester hydrochloride 5988-19-2, L-Dihydroorotic acid 6306-52-1, Valine methyl ester hydrochloride 6971-51-3, 3-Methoxybenzyl alcohol 7693-46-1, p-Nitrophenyl chloroformate 13360-57-1, Dimethylsulfamoyl chloride 13918-92-8, 2,4-Difluorobenzenesulfonyl chloride 15833-61-1, Tetrahydro-3-furanmethanol

16078-30-1, 1-Acetylindoline 16375-88-5, 4-Acetamidobenzyl alcohol
16420-13-6, Dimethylthiocarbamoyl chloride 16761-18-5,
4-Acetamido-3-chlorobenzenesulfonyl chloride 22037-28-1, 3-Bromofuran
23095-31-0, 3,4-Dimethoxybenzenesulfonyl chloride 24424-99-5,
Di-tert-butyl pyrocarbonate 28148-54-1, 2-Methylallylamine hydrochloride
30992-29-1 30996-79-3 49584-26-1, 4-Cyanobenzenesulfonyl chloride
52467-54-6 69812-29-9, 2-Acetamido-4-methyl-5-thiazolesulfonyl chloride
80466-79-1, 3,5-Dimethylisoxazole-4-sulfonyl chloride 80466-80-4,
2,4-Dimethylthiazole-5-sulfonyl chloride 86087-23-2 86087-24-3
88986-45-2, 3-Butenyl chloroformate 94108-56-2, 4-
Trifluoromethoxybenzenesulfonyl chloride 98737-29-2 126714-85-0
128018-43-9 128018-44-0 132388-57-9 151858-64-9 158627-30-6,
N,N-Disuccinimidyl carbonate 160233-26-1, 4-Fluoro-3-
acetamidobenzenesulfonyl chloride 160233-27-2 160233-28-3
160233-29-4 160233-30-7 169772-25-2 186463-41-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; preparation of heterocyclic sulfonamide derivs. as
inhibitors of HIV aspartyl protease)

RE.CNT 77 THERE ARE 77 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Anon; EP 0022118 1981 HCAPLUS
(2) Anon; JP 59046252 1984
(3) Anon; JP 59048449 1984 HCAPLUS
(4) Anon; EP 0181071 1986 HCAPLUS
(5) Anon; GB 2167759 1986 HCAPLUS
(6) Anon; DE 3542567 1986 HCAPLUS
(7) Anon; JP 61071830 1986 HCAPLUS
(8) Anon; EP 0264795 1988 HCAPLUS
(9) Anon; GB 2200115 1988 HCAPLUS
(10) Anon; EP 0346847 1989 HCAPLUS
(11) Anon; EP 0364804 1990 HCAPLUS
(12) Anon; WO 9007329 1990 HCAPLUS
(13) Anon; WO 9100725 1991 HCAPLUS
(14) Anon; WO 9118866 1991 HCAPLUS
(15) Anon; EP 0468641 1992 HCAPLUS
(16) Anon; EP 0486948 1992 HCAPLUS
(17) Anon; WO 9208688 1992 HCAPLUS
(18) Anon; WO 9208698 1992 HCAPLUS
(19) Anon; WO 9208699 1992 HCAPLUS
(20) Anon; WO 9208700 1992 HCAPLUS
(21) Anon; WO 9208701 1992 HCAPLUS
(22) Anon; WO 9217176 1992 HCAPLUS
(23) Anon; EP 0541168 1993 HCAPLUS
(24) Anon; WO 9323368 1993 HCAPLUS
(25) Anon; WO 9323379 1993 HCAPLUS
(26) Anon; WO 9323388 1993 HCAPLUS
(27) Anon; WO 9404491 1994 HCAPLUS
(28) Anon; WO 9404492 1994 HCAPLUS
(29) Anon; WO 9404493 1994 HCAPLUS
(30) Anon; WO 9410134 1994 HCAPLUS
(31) Anon; WO 9410136 1994 HCAPLUS
(32) Anon; WO 9418192 1994 HCAPLUS
(33) Anon; WO 9419322 1994 HCAPLUS
(34) Bindal, R; J Am Chem Soc 1990, V112, P7861 HCAPLUS
(35) Bone, R; J Am Chem Soc 1991, V113, P9382 HCAPLUS
(36) Borch, R; J Am Chem Soc 1971, V93, P2897 HCAPLUS
(37) Craig, J; Antiviral Chem and Chemotherapy 1990, V4(3), P161
(38) Crawford, S; J Virol 1985, V53, P899 HCAPLUS
(39) Cushman, M; J Org Chem 1991, V56, P4161 HCAPLUS
(40) Descamps; US 4330542 1982 HCAPLUS
(41) Dhanoa, D; Tetrahedron Lett 1992, V33, P1725 HCAPLUS
(42) Dreyer, G; Biochemistry 1992, V31, P6646 HCAPLUS
(43) Evans, B; J Org Chem 1985, V50, P4615 HCAPLUS
(44) Flynn, G; J Am Chem Soc 1989, V109, P7914
(45) Fontenot, G; Virology 1992, V190, P1 HCAPLUS
(46) Gassman, P; J Am Chem Soc 1982, V104, P5849 HCAPLUS
(47) Gilbert, E; Synthesis 1969, P3 HCAPLUS
(48) Goldblum, A; FEBS 1990, V261, P241 HCAPLUS
(49) Grobelny, D; Biochem Biophys Res Commun 1990, V169, P1111 HCAPLUS
(50) Hartman, G; J Med Chem 1992, V35, P3822 HCAPLUS
(51) Huff, J; Journal of Medicinal Chemistry 1991, V34(8), P2305 HCAPLUS
(52) Hui, K; FASEB 1991, V5, P2606 HCAPLUS
(53) Kempf; US 5354866 1994 HCAPLUS
(54) Kohl, N; Proc Natl Acad Sci USA 1988, V85, P4686 HCAPLUS
(55) Lin, X; J Biol Chem 1992, V267(24), P17257 HCAPLUS
(56) Manfredi, K; J Med Chem 1991, V34, P3395

(57) Marshall, F; Ann Ref Pharmacol Toxicol 1987, V27, P193
(58) Martin; US 5196438 1993 HCAPLUS
(59) Martin, J; Antiviral Research 1992, V17, P265 HCAPLUS
(60) Meek, T; Nature 1990, V343, P90 HCAPLUS
(61) Miller, M; Nature 1989, V337, P576 HCAPLUS
(62) Miller, M; Science 1989, V246, P1149 HCAPLUS
(63) Mitsuya, H; Proc Natl Acad Sci USA 1986, V83, P1911 HCAPLUS
(64) Mohrs; US 3743722 1973 HCAPLUS
(65) Murthy, K; J Biol Chem 1992, V267, P22770 HCAPLUS
(66) Nichols, J; J Phys Chem 1991, V95, P9803
(67) Overman, L; Tetrahedron Letters 1981, V195, P195
(68) Palca, J; Science 1990, V247, P410 MEDLINE
(69) Pearl, L; Nature 1987, V329, P329
(70) Popvic, M; Science 1984, V224, P497
(71) Posner, G; J Am Chem Soc 1977, V99, P8208 HCAPLUS
(72) Power, M; Science 1986, V231, P1567 HCAPLUS
(73) Roberts, N; Science 1990, V248, P358 HCAPLUS
(74) Ryono; US 4629724 1986 HCAPLUS
(75) Scharpe, S; Biochimie 1991, V73, P121 HCAPLUS
(76) Sharma, S; Anal Biochem 1991, V198, P363 HCAPLUS
(77) Toh, H; EMBO J 1985, V4, P1267 HCAPLUS

IT **160230-15-9P 160230-25-1P 160230-31-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic sulfonamide derivs. as inhibitors of HIV aspartyl protease)

RN 160230-15-9 HCAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[[(dimethylamino)sulfonyl](phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-25-1 HCAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[[(dimethylamino)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-31-9 HCAPLUS
CN 3-Thia-2,4,8,11-tetraazadodecan-12-oic acid, 6-hydroxy-2-methyl-10-(1-methylethyl)-4-(2-methylpropyl)-9-oxo-7-(phenylmethyl)-, 2-pyridinylmethyl ester, 3,3-dioxide, (6R,7S,10S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 160230-30-8
CMF C28 H43 N5 O6 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



L24 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:9928 HCAPLUS
DN 126:144117
ED Entered STN: 09 Jan 1997
TI Preparation of sulfonamide inhibitors of aspartyl protease
IN Tung, Roger D.; Murcko, Mark A.; Bhisetti, Govinda R.
PA Vertex Pharmaceuticals, Incorporated, USA
SO U.S., 87 pp., Cont.-in-part of U.S. Ser. No. 941,982,abandoned.
CODEN: USXXAM
DT Patent
LA English
IC ICM C07D407-12
ICS C07D307-20; A61K031-34
NCL 514473000
CC 27-16 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1, 28
FAN.CNT 5

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5585397	A	19961217	US 1993-142327	19931124 <--
WO 9405639	A1	19940317	WO 1993-US8458	19930907 <--
W: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
EP 885887	A2	19981223	EP 1998-113921	19930907 <--
EP 885887	A3	19990203		
EP 885887	B1	20030528		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
US 5783701	A	19980721	US 1995-393460	19950223 <--
US 5723490	A	19980303	US 1995-424819	19950419 <--
US 5856353	A	19990105	US 1995-477937	19950607 <--
US 6372778	B1	20020416	US 1995-484326	19950607 <--
US 5977137	A	19991102	US 1998-115394	19980714 <--
US 6004957	A	19991221	US 1998-121008	19980722 <--
US 6392046	B1	20020521	US 1999-409808	19990930 <--
US 2003064977	A1	20030403	US 2002-94763	20020308 <--
US 6720335	B2	20040413		
US 2003069222	A1	20030410	US 2002-94790	20020308 <--
US 2004167116	A1	20040826	US 2004-786997	20040224 <--

PRAI US 1992-941982 B2 19920908 <--
WO 1993-US8458 W 19930907
EP 1993-921428 A3 19930907
US 1993-142327 A2 19931124
US 1995-393460 B2 19950223
US 1995-484326 A3 19950607
US 1998-115394 A3 19980714
US 1999-409808 A3 19990930
US 2002-94763 A1 20020308

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES	
US 5585397	ICM	C07D407-12	
	ICS	C07D307-20; A61K031-34	
	NCL	514473000	
US 5585397	ECLA	C07D207/26C; C07D209/08; C07D213/30D; C07D215/48; C07D231/14; C07D239/22D2; C07D263/24; C07D271/08; C07D277/36; C07D307/12; C07D307/20; C07D403/12; C07D405/12; C07D405/12; C07D405/12; C07D409/12; C07D409/12; C07D409/14; C07D413/12; C07D413/12; C07D413/12; C07D413/12; C07D413/14; C07D413/14; C07D417/12; C07K005/06H2	<--
US 5783701	ECLA	C07D207/26C; C07D413/12; C07D413/12; C07D413/14; C07D413/14; C07D417/12; C07K005/06H2; C07D209/08; C07D213/30D; C07D215/48; C07D231/14; C07D263/24; C07D271/08; C07D277/36; C07D307/12; C07D307/20; C07D403/12; C07D405/12; C07D405/12; C07D409/12; C07D409/12; C07D409/14; C07D413/12; C07D413/12	<--
US 5856353	ECLA	C07D207/26C; C07D209/08; C07D213/30D; C07D215/48; C07D231/14; C07D239/22D2; C07D263/24; C07D071/08; C07D277/36; C07D307/12; C07D307/20; C07D403/12; C07D405/12; C07D405/2; C07D405/12; C07D409/12; C07D409/12; C07D409/14; C07D413/12; C07D413/12; C07D413/12; C07D413/12; C07D413/14; C07D413/14; C07D417/12; C07K005/06H2	<--
US 5977137	ECLA	C07K005/06H2	<--
US 6392046	ECLA	C07D207/26C; C07D213/30D; C07D215/48; C07D209/08; C07D231/14; C07D239/22D2; C07D263/24; C07D071/08; C07D277/36; C07D307/12; C07D307/20; C07D403/12; C07D405/12; C07D405/2; C07D405/12; C07D409/12; C07D409/12; C07D409/14; C07D413/12; C07D413/12; C07D413/12; C07D413/12; C07D413/14; C07D413/14; C07D417/12; C07K005/06H2	<--
US 2003064977	ECLA	C07D207/26C; C07D209/08; C07D213/30D; C07D215/48; C07D231/14; C07D239/22D2; C07D263/24; C07D071/08; C07D277/36; C07D307/12; C07D307/20; C07D403/12; C07D405/12; C07D405/2; C07D405/12; C07D409/12; C07D409/12; C07D409/14; C07D413/12; C07D413/12; C07D413/12; C07D413/12; C07D413/14; C07D413/14; C07D417/12; C07K005/06H2	<--
US 2003069222	ECLA	C07C307/06; C07D209/08; C07D213/30D; C07D215/48; C07D231/14; C07D239/22D2; C07D263/24; C07D021/08; C07D277/36; C07D307/12; C07D307/20; C07D403/12; C07D405/12; C07D405/1; C07D405/12; C07D409/12; C07D409/12; C07D409/14; C07D413/12; C07D413/12; C07D413/12; C07D413/12; C07D413/14; C07D413/14; C07D417/12; C07K005/06H2; C07C311/13; C07C311/18; C07C311/39; C07C311/46; C07D207/26C	<--

OS MARPAT 126:144117

GI



I

AB The title compds. I [A = 3-tetrahydrofuryloxycarbonyl; D' = (un)substituted alkyl; E = (un)substituted aryl] are prepared This invention also relates to pharmaceutical compns. comprising these compds. The compds. and pharmaceutical compns. of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and

consequently, may be advantageously used as antiviral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compds. of this invention and methods for screening compds. for anti-HIV activity. The title compds. inhibit HIV replication at concentration of .ltoreq. 100 nM.

ST sulfonamide prepn aspartyl protease inhibitor; HIV virucide sulfonamide prepn

IT Antiviral agents
Human immunodeficiency virus
(preparation of sulfonamide inhibitors of aspartyl protease with activity against HIV)

IT 157567-04-9P 157567-10-7P 159005-79-5P 159005-82-0P 159005-86-4P
160230-05-7P 160230-06-8P 160230-07-9P 160230-08-0P 160230-09-1P
160230-10-4P 160230-11-5P 160230-12-6P 160230-13-7P 160230-14-8P
160230-15-9P 160230-16-0P 160230-17-1P 160230-18-2P
160230-19-3P 160230-20-6P 160230-21-7P 160230-22-8P 160230-23-9P
160230-24-0P **160230-25-1P** 160230-27-3P 160230-29-5P
160230-31-9P 160230-33-1P 160230-35-3P 160230-36-4P
160230-37-5P 160230-38-6P 160230-39-7P 160230-40-0P 160230-41-1P
160230-42-2P 160230-43-3P 160230-44-4P 160230-45-5P 160230-46-6P
160230-47-7P 160230-48-8P 160230-49-9P 160230-50-2P 160230-51-3P
160230-52-4P 160230-53-5P 160230-54-6P 160230-55-7P 160230-56-8P
160230-57-9P 160230-58-0P 160230-59-1P 160230-60-4P 160230-61-5P
160230-62-6P 160230-63-7P 160230-64-8P 160230-65-9P 160230-66-0P
160230-67-1P 160230-68-2P 160230-69-3P 160230-70-6P 160230-71-7P
160230-72-8P 160230-73-9P 160230-74-0P 160230-75-1P 160230-76-2P
160230-77-3P 160230-78-4P 160230-79-5P 160230-80-8P 160230-81-9P
160230-82-0P 160230-83-1P 160230-84-2P 160230-85-3P 160230-86-4P
160230-87-5P 160230-88-6P 160230-89-7P 160230-91-1P 160230-92-2P
160230-93-3P 160230-94-4P 160230-95-5P 160230-97-7P 160230-98-8P
160231-00-5P 160231-01-6P 160231-02-7P 160231-03-8P 160231-04-9P
160231-05-0P 160231-06-1P 160231-07-2P 160231-08-3P 160231-10-7P
160231-11-8P 160231-12-9P 160231-13-0P 160231-14-1P 160231-15-2P
160231-16-3P 160231-17-4P 160231-18-5P 160231-19-6P 160231-20-9P
160231-21-0P 160231-22-1P 160231-23-2P 160231-24-3P 160231-25-4P
160231-26-5P 160231-27-6P 160231-28-7P 160231-29-8P 160231-30-1P
160231-32-3P 160231-33-4P 160231-36-7P 160231-37-8P 160231-38-9P
160231-39-0P 160231-40-3P 160231-41-4P 160231-42-5P 160231-43-6P
160231-44-7P 160231-45-8P 160231-47-0P 160231-48-1P 160231-49-2P
160231-51-6P 160231-52-7P 160231-53-8P 160231-54-9P 160231-55-0P
160231-56-1P 160231-57-2P 160231-58-3P 160231-59-4P 160231-60-7P
160231-61-8P 160231-62-9P 160231-63-0P 160231-64-1P 160231-65-2P
160231-66-3P 160231-67-4P 160231-68-5P 160231-69-6P 160231-71-0P
160231-72-1P 160231-73-2P 160231-74-3P 160231-75-4P 160231-76-5P
160231-77-6P 160231-78-7P 160231-79-8P 160231-80-1P 160231-81-2P
160231-82-3P 160231-83-4P 160231-84-5P 160231-85-6P 160231-86-7P
160231-87-8P 160231-88-9P 160231-89-0P 160231-90-3P 160231-91-4P
160231-92-5P 160231-93-6P 160231-95-8P 160231-96-9P 160333-38-0P
160333-40-4P 160333-41-5P 160333-42-6P 160333-43-7P 160333-44-8P
160333-45-9P 161814-49-9P 186462-96-4P 186463-14-9P 186463-15-0P
186463-16-1P 186463-17-2P 186463-18-3P 186463-19-4P 186463-20-7P
186464-71-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfonamide inhibitors of aspartyl protease)

IT 60-12-8, Phenethyl alcohol 74-89-5, Methylamine, reactions 75-44-5, Carbonic dichloride 78-81-9, Isobutylamine 79-22-1, Methyl chloroformate 93-10-7, Quinaldic acid 98-09-9, Benzenesulfonyl chloride 98-31-7, 3,4-Dichlorobenzenesulfonyl chloride 98-59-9, p-Toluenesulfonyl chloride 98-68-0, 4-Methoxybenzenesulfonyl chloride 98-74-8, p-Nitrobenzenesulfonyl chloride 98-79-3, L-Pyroglutamic acid 99-16-1 100-46-9, Benzylamine, reactions 100-55-0, 3-Pyridylcarbinol 105-13-5, 4-Methoxybenzyl alcohol 108-23-6, Isopropyl chloroformate 109-61-5, Propyl chloroformate 110-89-4, Piperidine, reactions 110-91-8, Morpholine, reactions 121-47-1, 3-Aminobenzenesulfonic acid 121-60-8, 4-Acetamidobenzenesulfonyl chloride 124-63-0, Methanesulfonyl chloride 274-09-9, 1,3-Benzodioxole 349-71-3, 3-Fluoro-4-acetamidobenzenesulfonyl chloride 453-20-3 496-16-2, 2,3-Dihydrobenzofuran 501-53-1, Benzyl chloroformate 541-41-3, Ethyl chloroformate 543-27-1, Isobutyl chloroformate 585-47-7, 1,3-Benzenedisulfonyl dichloride 586-98-1, 2-Pyridylcarbinol 612-16-8, 2-Methoxybenzyl alcohol 617-89-0, Furfurylamine 628-12-6, 2-Methoxyethyl chloroformate 638-32-4, Succinamic acid 701-99-5, Phenoxyacetyl chloride 768-09-2, 2,1,3-Benzoxadiazol-5-ol 777-44-6, 3-Trifluoromethylbenzenesulfonyl chloride 1003-03-8, Cyclopentylamine

1445-91-6, (s)-(-)-1-Phenylethanol 1483-28-9, 2,5-Dimethoxybenzenesulfonyl chloride 1517-69-7, (+)-1-Phenylethanol 1656-44-6, 2,4-Dinitrobenzenesulfonyl chloride 1885-14-9, Phenyl chloroformate 1939-99-7, .alpha.-Toluenesulfonyl chloride 2905-21-7, 2-Fluorobenzenesulfonyl chloride 2937-50-0, Allyl chloroformate 2942-58-7, Diethyl cyanophosphonate 3160-59-6 3173-56-6, Benzyl isocyanate 3218-02-8, Cyclohexanemethanamine 3445-11-2 3513-81-3, 2-Methylene-1,3-propanediol 4025-64-3, 3-Chlorosulfonylbenzoic acid 4254-02-8, Cyclopentanecarbonitrile 4319-49-7, N-Aminomorpholine 5070-13-3 5680-80-8, Serine methyl ester hydrochloride 5988-19-2, L-Dihydroorotic acid 6306-52-1, Valine methyl ester hydrochloride 6971-51-3, 3-Methoxybenzyl alcohol 7693-46-1, p-Nitrophenyl chloroformate 13360-57-1, Dimethylsulfamoyl chloride 13918-92-8, 2,4-Difluorobenzenesulfonyl chloride 15833-61-1, Tetrahydro-3-furanmethanol 16078-30-1, 1-Acetylindoline 16375-88-5, 4-Acetamidobenzyl alcohol 16420-13-6, Dimethylthiocarbamoyl chloride 16761-18-5, 4-Acetamido-3-chlorobenzenesulfonyl chloride 22037-28-1, 3-Bromofuran 23095-31-0, 3,4-Dimethoxybenzenesulfonyl chloride 24424-99-5, Di-tert-butyl pyrocarbonate 28148-54-1, 2-Methylallylamine hydrochloride 30992-29-1 30996-79-3 49584-26-1, 4-Cyanobenzenesulfonyl chloride 52467-54-6 69812-29-9, 2-Acetamido-4-methyl-5-thiazolesulfonyl chloride 80466-79-1, 3,5-Dimethylisoxazole-4-sulfonyl chloride 80466-80-4, 2,4-Dimethylthiazole-5-sulfonyl chloride 86087-23-2 86087-24-3 88986-45-2, 3-Butenyl chloroformate 94108-56-2, 4-Trifluoromethoxybenzenesulfonyl chloride 98737-29-2 126714-85-0 128018-43-9 128018-44-0 132388-57-9 151858-64-9 158627-30-6, N,N-Disuccinimidyl carbonate 160233-26-1, 4-Fluoro-3-acetamidobenzenesulfonyl chloride 160233-27-2 160233-28-3 160233-29-4 160233-30-7 169772-25-2 186463-41-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of sulfonamide inhibitors of aspartyl protease)

IT 1080-11-1P 1828-66-6P, 4-Morpholinesulfonyl chloride 4295-99-2P 6053-81-2P, Aminomethylcyclopentane 23905-46-6P 25506-37-0P 30293-86-8P 32939-32-5P 35856-62-3P, 1-Piperidinesulfonyl chloride 52206-05-0P 52665-49-3P, 3-Furansulfonyl chloride 54981-39-4P 87001-32-9P, 4-Benzyloxybenzenesulfonyl chloride 102522-17-8P 114322-14-4P, 2,1,3-Benzoxadiazole-4-sulfonyl chloride 115010-10-1P, 1,3-Benzodioxole-5-sulfonyl chloride 115010-11-2P, 2,3-Dihydrobenzofuran-5-sulfonyl chloride 116586-32-4P 130290-79-8P 132682-22-5P 132682-23-6P 134807-06-0P 134807-20-8P 138499-08-8P 143224-83-3P 158851-95-7P 159006-03-8P 159006-20-9P 159141-66-9P 160231-97-0P 160231-98-1P 160231-99-2P 160232-00-8P 160232-01-9P 160232-02-0P 160232-03-1P 160232-05-3P 160232-06-4P 160232-08-6P 160232-09-7P 160232-10-0P 160232-11-1P 160232-12-2P 160232-13-3P 160232-14-4P 160232-15-5P, 2,1,3-Benzoxadiazole-4-sulfonic acid 160232-17-7P 160232-18-8P 160232-19-9P, 2,1,3-Benzoxadiazole-5-thiol 160232-20-2P, 2,1,3-Benzoxadiazole-5-sulfonyl chloride 160232-22-4P 160232-23-5P 160232-24-6P 160232-25-7P 160232-26-8P 160232-27-9P 160232-28-0P 160232-29-1P 160232-30-4P 160232-31-5P 160232-32-6P 160232-33-7P 160232-34-8P 160232-36-0P 160232-37-1P 160232-38-2P 160232-39-3P 160232-40-6P 160232-41-7P 160232-42-8P 160232-43-9P 160232-44-0P 160232-45-1P 160232-46-2P 160232-47-3P 160232-48-4P 160232-49-5P 160232-50-8P 160232-51-9P 160232-52-0P 160232-53-1P 160232-54-2P 160232-56-4P 160232-60-0P 160232-61-1P 160232-62-2P 160232-63-3P 160232-64-4P 160232-65-5P 160232-66-6P 160232-68-8P 160232-69-9P 160232-70-2P 160232-71-3P 160232-72-4P 160232-73-5P 160232-74-6P 160232-75-7P 160232-76-8P 160232-77-9P 160232-78-0P 160232-79-1P 160232-80-4P 160232-81-5P 160232-82-6P 160232-83-7P 160232-84-8P 160232-85-9P 160232-86-0P 160232-87-1P 160232-89-3P 160232-91-7P 160232-92-8P 160232-93-9P 160232-94-0P 160232-95-1P 160232-96-2P 160232-97-3P 160232-98-4P 160232-99-5P 160233-00-1P 160233-01-2P 160233-02-3P 160233-03-4P 160233-04-5P 160233-05-6P 160233-06-7P 160233-07-8P 160233-08-9P 160233-09-0P 160233-12-5P 160233-13-6P 160233-19-2P 160233-21-6P 160233-22-7P 160233-23-8P 160233-24-9P 160233-31-8P 160333-46-0P 160333-47-1P 160333-49-3P 160333-50-6P 184357-14-0P 184357-17-3P 186463-21-8P 186463-22-9P 186463-23-0P 186463-24-1P 186463-25-2P 186463-26-3P 186463-27-4P 186463-28-5P 186463-29-6P 186463-30-9P 186463-31-0P 186463-32-1P 186463-33-2P 186463-35-4P 186463-37-6P 186463-39-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of sulfonamide inhibitors of aspartyl protease)

IT 78169-47-8, Aspartyl protease
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)

(preparation of sulfonamide inhibitors of aspartyl protease with activity against HIV)

IT **160230-15-9P 160230-25-1P 160230-31-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfonamide inhibitors of aspartyl protease)

RN 160230-15-9 HCAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[[(dimethylamino)sulfonyl](phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-25-1 HCAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[[(dimethylamino)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-31-9 HCAPLUS
CN 3-Thia-2,4,8,11-tetraazadodecan-12-oic acid, 6-hydroxy-2-methyl-10-(1-methylethyl)-4-(2-methylpropyl)-9-oxo-7-(phenylmethyl)-, 2-pyridinylmethyl ester, 3,3-dioxide, (6R,7S,10S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 160230-30-8
CMF C28 H43 N5 O6 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



L24 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1995:293723 HCAPLUS
DN 122:81141
ED Entered STN: 14 Jan 1995
TI Preparation of heterocyclylarylsulfonamide inhibitors of HIV-aspartyl protease
IN Tung, Roger D.; Murcko, Mark A.; Bhisetti, Govinda Rao
PA Vertex Pharmaceuticals Inc., USA
SO PCT Int. Appl., 291 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07D215-48
ICS A61K031-16; C07D413-12; C07D417-12; C07D409-14; C07D409-12; C07D213-30; C07C311-41; C07D207-26; C07D305-12; C07D239-54; C07D277-36
CC 27-17 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1
FAN.CNT 5

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9405639	A1	19940317	WO 1993-US8458	19930907 <--
W: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
LT 3302	B	19950626	LT 1993-917	19930901 <--
IL 106927	A1	20010111	IL 1993-106927	19930906 <--
EP 659181	A1	19950628	EP 1993-921428	19930907 <--
EP 659181	B1	19990407		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 08501299	T2	19960213	JP 1993-507525	19930907 <--
JP 3012002	B2	20000221		
HU 71892	A2	19960228	HU 1995-685	19930907 <--
AU 691160	B2	19980514	AU 1993-48520	19930907 <--
AU 9348520	A1	19940329		
EP 885887	A2	19981223	EP 1998-113921	19930907 <--
EP 885887	A3	19990203		
EP 885887	B1	20030528		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
AT 178598	E	19990415	AT 1993-921428	19930907 <--
ES 2131589	T3	19990801	ES 1993-921428	19930907 <--
RU 2135496	C1	19990827	RU 1995-109928	19930907 <--
JP 3012002	B2	20000221	JP 1994-507525	19930907 <--
SK 281360	B6	20010212	SK 1995-293	19930907 <--
CZ 289475	B6	20020116	CZ 1995-587	19930907 <--
CA 2143208	C	20030107	CA 1993-2143208	19930907 <--
AT 241602	E	20030615	AT 1998-113921	19930907 <--
PL 185635	B1	20030630	PL 1993-307858	19930907 <--
RO 118747	B1	20031030	RO 1995-479	19930907 <--
PT 885887	T	20031031	PT 1998-113921	19930907 <--
ES 2200243	T3	20040301	ES 1998-113921	19930907 <--
CN 1087347	A	19940601	CN 1993-117370	19930908 <--
CN 1061339	B	20010131		
ZA 9308470	A	19940620	ZA 1993-8470	19931112 <--
US 5585397	A	19961217	US 1993-142327	19931124 <--
FI 9501059	A	19950418	FI 1995-1059	19950307 <--
NO 9500876	A	19950508	NO 1995-876	19950307 <--
HK 1012631	A1	20000623	HK 1998-113971	19981217 <--
PRAI US 1992-941982	A2	19920908	<--	

EP 1993-921428 A3 19930907
WO 1993-US8458 W 19930907

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9405639	ICM	C07D215-48
	ICS	A61K031-16; C07D413-12; C07D417-12; C07D409-14; C07D409-12; C07D213-30; C07C311-41; C07D207-26; C07D305-12; C07D239-54; C07D277-36
US 5585397	ECLA	C07D207/26C; C07D209/08; C07D213/30D; C07D215/48; C07D231/14; C07D239/22D2; C07D263/24; C07D271/08; C07D277/36; C07D307/12; C07D307/20; C07D403/12; C07D405/12; C07D405/12; C07D405/12; C07D409/12; C07D409/12; C07D409/14; C07D413/12; C07D413/12; C07D413/12; C07D413/12; C07D413/14; C07D413/14; C07D417/12; C07K005/06H2 <--

OS MARPAT 122:81141
GI



I



II

AB Title compds. A(B)xNHCH(D)CH(OH)CH2N(D')SO2E (A = H, Het, R1-Het, (substituted)R1-C1-6 alkyl, (substituted) R1-C2-6 alkenyl wherein R1 = CO, SO2, COCO, O2C, etc., Het = C5-7 cycloalkyl, C5-7 cycloalkenyl, C6-10 aryl, (substituted) 5-7-membered heterocyclyl; R2 = H, (Ar)-C1-3 alkyl; B = NR2CR3CO, null wherein R3 = H, (substituted)Het or C1-6 alkyl or C2-6 alkenyl or C3-6 cycloalkyl or C5-6 cycloalkenyl; x = 0,1; D, D' = Ar, (substituted) C1-4 alkyl wherein Ar = Ph, (substituted) 3-6-membered carbocyclyl or 5-6-membered heterocyclyl; E = Het-O, Het-Het, (substituted) C1-6 alkyl or C2-6 alkenyl, C3-6 carbocyclyl) useful also against viral infection of HIV-2, HIV-2, or HTLV, are prepared 4,3-(AcNH)FC6H3SO2Cl and syn-I (A = quinolin-2-ylcarbonyl, D' = Me2CHCH2) (preparation given) in CH2Cl2 was treated with F3CCO2H followed by NaHCO3 and 4-FC6H4SO2Cl to give the title compound II which inhibited HIV-1 protease with IC50 of <0.1 nM.

ST heterocyclylarylsulfonamide prepn antiviral; aspartyl protease HIV inhibition heterocyclylarylsumfonamide; HIV treatment heterocyclylarylsumfonamide

IT Virucides and Virustats
(sulfonamide inhibitors of HIV-aspartyl protease)

IT Sulfonamides
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(sulfonamide inhibitors of HIV-aspartyl protease)

IT Virus, animal
(human T-cell leukemia, inhibitors, heterocyclylarylsulfonamides)

IT Virus, animal
(human immunodeficiency 1, inhibitors, heterocyclylarylsulfonamides)

IT Virus, animal
(human immunodeficiency 2, inhibitors, heterocyclylarylsulfonamides)

IT 78169-47-8, Aspartic proteinase
RL: RCT (Reactant); RACT (Reactant or reagent)
(of HIV-1, inhibitors, heterocyclylarylsulfonamides)

IT 1080-11-1P 1828-66-6P, 4-Morpholinesulfonyl chloride 4295-99-2P 6053-81-2P, Cyclopentanemethanamine 23905-46-6P 25506-37-0P

32939-32-5P 35856-62-3P, 1-Piperidinesulfonyl chloride 52206-05-0P
52665-49-3P, 3-Furansulfonyl chloride 54981-39-4P 87001-32-9P
114322-14-4P, 2,1,3-Benzoxadiazole-4-sulfonyl chloride 115010-10-1P,
1,3-Benzodioxole-5-sulfonyl chloride 115010-11-2P 116586-32-4P
130290-79-8P 132682-22-5P 134807-06-0P 134807-20-8P 138499-08-8P
143224-83-3P 144542-44-9P 158851-95-7P 159006-03-8P 159006-20-9P
159141-66-9P 160230-69-3P 160231-97-0P 160231-98-1P 160231-99-2P
160232-00-8P 160232-01-9P 160232-02-0P 160232-03-1P 160232-04-2P
160232-05-3P 160232-06-4P 160232-07-5P 160232-08-6P 160232-09-7P
160232-10-0P 160232-11-1P 160232-12-2P 160232-13-3P 160232-14-4P
160232-15-5P, 2,1,3-Benzoxadiazole-4-sulfonic acid 160232-16-6P
160232-17-7P 160232-18-8P 160232-19-9P, 2,1,3-Benzoxadiazole-5-thiol
160232-20-2P, 2,1,3-Benzoxadiazole-5-sulfonyl chloride 160232-21-3P
160232-22-4P 160232-23-5P 160232-24-6P 160232-25-7P 160232-26-8P
160232-27-9P 160232-28-0P 160232-29-1P 160232-30-4P 160232-31-5P
160232-32-6P 160232-33-7P 160232-34-8P 160232-35-9P 160232-36-0P
160232-37-1P 160232-38-2P 160232-39-3P 160232-40-6P 160232-41-7P
160232-42-8P 160232-43-9P 160232-44-0P 160232-45-1P 160232-46-2P
160232-47-3P 160232-48-4P 160232-49-5P 160232-50-8P 160232-51-9P
160232-52-0P 160232-53-1P 160232-54-2P 160232-55-3P 160232-56-4P
160232-57-5P 160232-58-6P 160232-59-7P 160232-60-0P 160232-61-1P
160232-62-2P 160232-63-3P 160232-64-4P 160232-65-5P 160232-66-6P
160232-67-7P 160232-68-8P 160232-69-9P 160232-70-2P 160232-71-3P
160232-72-4P 160232-73-5P 160232-74-6P 160232-75-7P 160232-76-8P
160232-77-9P 160232-78-0P 160232-79-1P 160232-80-4P 160232-81-5P
160232-82-6P 160232-83-7P 160232-84-8P 160232-85-9P 160232-86-0P
160232-87-1P 160232-88-2P 160232-89-3P 160232-90-6P 160232-91-7P
160232-92-8P 160232-93-9P 160232-94-0P 160232-95-1P 160232-96-2P
160232-97-3P 160232-98-4P 160232-99-5P 160233-00-1P 160233-01-2P
160233-02-3P 160233-03-4P 160233-04-5P 160233-05-6P 160233-06-7P
160233-07-8P 160233-08-9P 160233-09-0P 160233-10-3P 160233-11-4P
160233-12-5P 160233-13-6P 160233-14-7P 160233-15-8P 160233-16-9P
160233-17-0P 160233-18-1P 160233-19-2P 160233-20-5P 160233-21-6P
160233-22-7P 160233-23-8P 160233-24-9P 160233-31-8P 160333-46-0P
160333-47-1P 160333-48-2P 160333-49-3P 160333-50-6P 160333-51-7P
160333-52-8P 160333-53-9P 160333-54-0P 160333-56-2P 160333-57-3P
160333-58-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and reaction of, in preparation of HIV-1 protease inhibitors)

IT 157567-04-9P 157567-10-7P 159005-79-5P 159005-82-0P 159005-86-4P
160230-05-7P 160230-06-8P 160230-07-9P 160230-08-0P 160230-09-1P
160230-10-4P 160230-11-5P 160230-12-6P 160230-13-7P 160230-14-8P
160230-15-9P 160230-16-0P 160230-17-1P 160230-18-2P
160230-19-3P 160230-20-6P 160230-21-7P 160230-22-8P 160230-23-9P
160230-24-0P **160230-25-1P** 160230-27-3P 160230-29-5P
160230-31-9P 160230-33-1P 160230-35-3P 160230-36-4P
160230-37-5P 160230-38-6P 160230-39-7P 160230-40-0P 160230-41-1P
160230-42-2P 160230-43-3P 160230-44-4P 160230-45-5P 160230-46-6P
160230-47-7P 160230-48-8P 160230-49-9P 160230-50-2P 160230-51-3P
160230-52-4P 160230-53-5P 160230-54-6P 160230-55-7P 160230-56-8P
160230-57-9P 160230-58-0P 160230-59-1P 160230-60-4P 160230-61-5P
160230-62-6P 160230-63-7P 160230-64-8P 160230-65-9P 160230-66-0P
160230-67-1P 160230-68-2P 160230-69-3P 160230-70-6P 160230-71-7P
160230-72-8P 160230-73-9P 160230-74-0P 160230-75-1P 160230-76-2P
160230-77-3P 160230-78-4P 160230-79-5P 160230-80-8P 160230-81-9P
160230-82-0P 160230-83-1P 160230-84-2P 160230-85-3P 160230-86-4P
160230-87-5P 160230-88-6P 160230-89-7P 160230-90-0P 160230-91-1P
160230-92-2P 160230-93-3P 160230-94-4P 160230-95-5P 160230-96-6P
160230-97-7P 160230-98-8P 160230-99-9P 160231-00-5P 160231-01-6P
160231-02-7P 160231-03-8P 160231-04-9P 160231-05-0P 160231-06-1P
160231-07-2P 160231-08-3P 160231-10-7P 160231-11-8P 160231-12-9P
160231-13-0P 160231-14-1P 160231-15-2P 160231-16-3P 160231-17-4P
160231-18-5P 160231-19-6P 160231-20-9P 160231-21-0P 160231-22-1P
160231-23-2P 160231-24-3P 160231-25-4P 160231-26-5P 160231-27-6P
160231-28-7P 160231-29-8P 160231-30-1P 160231-31-2P 160231-32-3P
160231-33-4P 160231-34-5P 160231-35-6P 160231-36-7P 160231-37-8P
160231-38-9P 160231-39-0P 160231-40-3P 160231-41-4P 160231-42-5P
160231-43-6P 160231-44-7P 160231-45-8P 160231-47-0P 160231-48-1P
160231-49-2P 160231-51-6P 160231-52-7P 160231-53-8P 160231-54-9P
160231-55-0P 160231-56-1P 160231-57-2P 160231-58-3P 160231-59-4P
160231-60-7P 160231-61-8P 160231-62-9P 160231-63-0P 160231-64-1P
160231-65-2P 160231-66-3P 160231-67-4P 160231-68-5P 160231-69-6P
160231-70-9P 160231-71-0P 160231-72-1P 160231-73-2P 160231-74-3P
160231-75-4P 160231-76-5P 160231-77-6P 160231-78-7P 160231-79-8P
160231-80-1P 160231-81-2P 160231-82-3P 160231-83-4P 160231-84-5P

160231-85-6P 160231-86-7P 160231-87-8P 160231-88-9P 160231-89-0P
160231-90-3P 160231-91-4P 160231-92-5P 160231-93-6P 160231-94-7P
160231-95-8P 160231-96-9P 160333-37-9P 160333-38-0P 160333-39-1P
160333-40-4P 160333-41-5P 160333-42-6P 160333-43-7P 160333-44-8P
160333-45-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of as HIV-1 protease inhibitor)

IT 60-12-8, Phenethyl alcohol 78-81-9, Isobutylamine 93-10-7, Quinaldic acid 98-31-7, 3,4-Dichlorobenzenesulfonyl chloride 98-68-0, 4-Methoxybenzenesulfonyl chloride 98-79-3 99-16-1 100-55-0, 3-Pyridyl carbinol 105-13-5, 4-Methoxybenzyl alcohol 108-23-6, Isopropyl chloroformate 109-61-5, n-Propyl chloroformate 110-89-4, Piperidine, reactions 121-47-1, 3-Aminobenzenesulfonic acid 121-60-8, N-Acetylsulfanilyl chloride 274-09-9, 1,3-Benzodioxole 349-71-3, 3-Fluoro-4-acetamidobenzenesulfonyl chloride 349-88-2, 4-Fluorobenzenesulfonyl chloride 453-20-3, (RS)-3-hydroxytetrahydrofuran 496-16-2, 2,3-Dihydrobenzofuran 501-53-1, Benzyl chloroformate 513-42-8, Methallyl alcohol 543-27-1, Isobutyl chloroformate 585-47-7, 1,3-Benzenedisulfonyl dichloride 586-95-8, 4-Pyridyl carbinol 586-98-1, 2-Pyridyl carbinol 612-16-8, 2-Methoxybenzyl alcohol 617-89-0, Furfurylamine 628-12-6, 2-Methoxyethyl chloroformate 638-32-4, Succinamic acid 701-99-5, Phenoxyacetyl chloride 768-09-2, Benzofurazan-5-ol 777-44-6, 3-(Trifluoromethyl)benzenesulfonyl chloride 946-80-5, Benzyl phenyl ether 1003-03-8, Cyclopentylamine 1445-91-6 1483-28-9, 2,5-Dimethoxybenzenesulfonyl chloride 1493-13-6, Trifluoromethanesulfonic acid 1517-69-7 1656-44-6, 2,4-Dinitrobenzenesulfonyl chloride 1885-14-9, Phenyl chloroformate 2799-21-5 2905-21-7, 2-Fluorobenzenesulfonyl chloride 2937-50-0, Allyl chloroformate 3160-59-6 3173-56-6, Benzyl isocyanate 3445-11-2, 1-(2-Hydroxyethyl)-2-pyrrolidinone 3513-81-3, 2-Methylene-1,3-propanediol 4025-64-3, 3-(Chlorosulfonyl)benzoic acid 4254-02-8, Cyclopentanecarbonitrile 4319-49-7, N-Aminomorpholine 5070-13-3 5680-80-8, Serine methyl ester hydrochloride 5988-19-2, L-Dihydroorotic acid 6306-52-1, Valine methyl ester hydrochloride 6971-51-3, 3-Methoxybenzyl alcohol 7252-53-1, Cyclopropylmethylamine hydrochloride 7633-32-1 7693-46-1, p-Nitrophenyl chloroformate 13258-63-4, 4-Pyridineethanamine 13360-57-1, Dimethylsulfamoyl chloride 13918-92-8, 2,4-Difluorobenzenesulfonyl chloride 16078-30-1, 1-Acetylindoline 16375-88-5, 4-Acetamidobenzyl alcohol 16420-13-6, Dimethylthiocarbamoyl chloride 16761-18-5, 4-Acetamido-3-chlorobenzenesulfonyl chloride 22037-28-1, 3-Bromofuran 23095-31-0, 3,4-Dimethoxybenzenesulfonyl chloride 24424-99-5, Di-tert-butyl pyrocarbonate 28148-54-1 30992-29-1 52467-54-6 69812-29-9, 2-Acetamido-4-methyl-5-thiazolesulfonyl chloride 74124-79-1, N,N'-Disuccinimidyl carbonate 80466-79-1, 3,5-Dimethylisoxazole-4-sulfonyl chloride 80466-80-4, 2,4-Dimethylthiazole-5-sulfonyl chloride 86087-23-2, (S)-(+)-3-Hydroxytetrahydrofuran 88986-45-2 94108-56-2 98737-29-2 126714-85-0 128018-43-9 128018-44-0 132388-57-9 145758-05-0, 3,4-Difluorobenzenesulfonyl chloride 151858-64-9 160232-67-7 160233-25-0 160233-26-1, 4-Fluoro-3-acetamidobenzenesulfonyl chloride 160233-27-2 160233-28-3 160233-29-4 160233-30-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of HIV-1 protease inhibitors)

IT **160230-15-9P 160230-25-1P 160230-31-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of as HIV-1 protease inhibitor)

RN 160230-15-9 HCAPLUS

CN Butanediamide, N1-[(1S,2R)-3-[[(dimethylamino)sulfonyl](phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-25-1 HCAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[[(dimethylamino)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-31-9 HCAPLUS
CN 3-Thia-2,4,8,11-tetraazadodecan-12-oic acid, 6-hydroxy-2-methyl-10-(1-methylethyl)-4-(2-methylpropyl)-9-oxo-7-(phenylmethyl)-, 2-pyridinylmethyl ester, 3,3-dioxide, (6R,7S,10S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 160230-30-8
CMF C28 H43 N5 O6 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



```
=> b home
FILE 'HOME' ENTERED AT 13:17:54 ON 15 OCT 2004

=>
```

```
=> d his

     (FILE 'HOME' ENTERED AT 12:35:25 ON 15 OCT 2004)

     FILE 'HCAPLUS' ENTERED AT 12:35:55 ON 15 OCT 2004
L1             1 US2004017165 3/PN

     FILE 'REGISTRY' ENTERED AT 12:36:16 ON 15 OCT 2004

     FILE 'HCAPLUS' ENTERED AT 12:36:18 ON 15 OCT 2004
L2             TRA L1 1- RN :       49 TERMS

     FILE 'REGISTRY' ENTERED AT 12:36:18 ON 15 OCT 2004
L3            49 SEA L2

     FILE 'WPIX' ENTERED AT 12:36:24 ON 15 OCT 2004
L4             1 US2004017165 3/PN

=> b hcap
FILE 'HCAPLUS' ENTERED AT 12:36:59 ON 15 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 15 Oct 2004  VOL 141 ISS 17
FILE LAST UPDATED: 14 Oct 2004  (20041014/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.


=> d all l1

L1   ANSWER 1 OF 1  HCAPLUS  COPYRIGHT 2004 ACS on STN
AN   1996:725344  HCAPLUS
DN   126:75247
ED   Entered STN:  11 Dec 1996
TI   Preparation of .alpha.- and .beta.-amino acid hydroxyethylamino sulfonyl
     urea derivatives as retroviral protease inhibitors
IN   Vazquez, Michael L.; Mueller, Richard A.; Talley, John J.; Getman, Daniel
     P.; Decrescenzo, Gary A.; Sun, Eric T.
PA   G.D. Searle and Co., USA
SO   U.S., 37 pp.
     CODEN: USXXAM
DT   Patent
LA   English
IC   ICM  C07D401-12
     ICS  C07D413-12; C07D417-12; A61K031-47; A61K031-505; A61K031-54
NCL  514314000
CC   34-3 (Amino Acids, Peptides, and Proteins)
     Section cross-reference(s): 1, 7, 63
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.          DATE
     --------------      ----   --------    --------------------     --------
PI   US 5578606           A     19961126    US 1992-968712           19921030
     US 6022872           A     20000208    US 1996-709069           19960906
     US 6211176           B1    20010403    US 1999-345739           19990701
     US 6403585           B1    20020611    US 2000-731911           20001208
     US 2003144342        A1    20030731    US 2002-138534           20020506
     US 6683648           B2    20040127
     US 2004174653        A1    20040902    US 2003-689513           20031021
PRAI US 1992-968712       A3    19921030
     US 1996-709069       A1    19960906
     US 1999-345739       A1    19990701
     US 2000-731911       A1    20001208
```

US 2002-138534 A1 20020506

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 5578606	ICM	C07D401-12
	ICS	C07D413-12; C07D417-12; A61K031-47; A61K031-505; A61K031-54
	NCL	514314000
US 5578606	ECLA	C07C307/06; C07D239/38; C07D307/85; C07K005/06A1A1; C07K005/06A1A3; C07K005/06H2; C07K005/06T; C07D023/42C; C07D215/48; C07D215/50; C07D215/54; C07D235/06B
US 6403585	ECLA	C07C307/06; C07D213/42C; C07D215/48; C07D215/50; C07D215/54; C07D235/06B; C07D239/38; C07D030/85; C07K005/06A1A3; C07K005/06A1A1; C07K005/06H2; C07K005/06T
US 2003144342	ECLA	C07C307/06; C07D213/42C; C07D215/48; C07D215/50; C07D215/54; C07D235/06B; C07D239/38; C07D030/85; C07K005/06A1A3; C07K005/06A1A1; C07K005/06H2; C07K005/06T

OS MARPAT 126:75247

GI



I



II



III

AB .alpha.- And .beta.-amino acid hydroxyethylamino sulfonyl urea derivative compds., e.g. I [R3 = C1-8 alkyl, (un)substituted C1-8 alkylphenyl, C1-8 heteroaralkyl; R8 = (un)substituted Ph, heterocyclyl, CN, OH, CO2H, C1-8 alkylthio, (un)substituted phenylsulfonyl, C1-8 alkanoyl, C1-8 alkoxycarbonyl, C1-8 dialkylaminocarbonyl, N-C1-8- alkyl-N-phenylcarbamoyl, 2-heterocyclylethoxy, heterocyclyl; n = 0-2], are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. Thus, coupling of protected amino(hydroxy)phenylbutylamine II (Z = PhCH2O2C) (prepared in 3 steps from chloromethyl ketone Z-L-Phe-CH2Cl) with ClSO2NHCMe2CO2Me, followed by hydrogenolysis and coupling with Z-Asn-OH gave inhibitor III.

ST retroviral protease inhibitor hydroxyethylaminosulfonyl urea peptide; protease inhibitor hydroxyethylaminosulfonyl urea peptide prepn; HIV virucide hydroxyethylaminosulfonyl urea peptide prepn

IT Antiviral agents
Human immunodeficiency virus 1
(preparation of hydroxyethylamino sulfonyl urea peptide derivs. as retroviral protease inhibitors)

IT 185256-67-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hydroxyethylamino sulfonyl urea peptide derivs. as retroviral protease inhibitors)

IT 63-91-2, L-Phenylalanine, reactions 78-81-9, Isobutylamine 105-13-5, 4-Methoxybenzyl alcohol 107-85-7, Isoamylamine 2170-03-8 2304-96-3 26049-94-5 152714-71-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of hydroxyethylamino sulfonyl urea peptide derivs. as retroviral protease inhibitors)

IT 107-95-9P, .beta.-Alanine 498-25-9P 541-48-0P, 3-Aminobutanoic acid 3377-31-9P 3653-34-7P 4385-92-6P 5699-54-7P 15099-85-1P 16934-21-7P 32723-74-3P 32723-76-5P 53874-24-1P 60427-77-2P

65414-77-9P 75081-40-2P 83509-04-0P 91247-38-0P 95598-13-3P
100869-07-6P 111060-52-7P 111060-64-1P 127927-43-9P 128018-43-9P
128018-44-0P 130165-86-5P 132605-93-7P 132605-97-1P 132605-98-2P
132696-45-8P 143224-62-8P 143224-86-6P 143225-04-1P 160191-57-1P
185256-61-5P 185256-62-6P 185256-63-7P 185256-64-8P 185256-65-9P
185256-66-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of hydroxyethylamino sulfonyl urea peptide derivs. as retroviral protease inhibitors)

IT 9001-92-7, Protease
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(retroviral; preparation of hydroxyethylamino sulfonyl urea peptide derivs. as retroviral protease inhibitors)

=> b wpix
FILE 'WPIX' ENTERED AT 12:37:06 ON 15 OCT 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE LAST UPDATED: 11 OCT 2004 <20041011/UP>
MOST RECENT DERWENT UPDATE: 200465 <200465/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE, PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE http://thomsonderwent.com/coverage/latestupdates/ <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER GUIDES, PLEASE VISIT:
http://thomsonderwent.com/support/userguides/ <<<

>>> NEW! FAST-ALERTING ACCESS TO NEWLY-PUBLISHED PATENT DOCUMENTATION NOW AVAILABLE IN DERWENT WORLD PATENTS INDEX FIRST VIEW - FILE WPIFV.
FOR FURTHER DETAILS: http://www.thomsonderwent.com/dwpifv <<<

>>> NEW DISPLAY FORMAT HITSTR ADDED ALLOWING DISPLAY OF HIT STRUCTURES WITHIN THE BIBLIOGRAPHIC DOCUMENT <<<

=> d all l4

L4 ANSWER 1 OF 1 WPIX COPYRIGHT 2004 THE THOMSON CORP on STN
AN 2004-651696 [63] WPIX
CR 1997-020446 [02]; 2000-160388 [14]; 2001-388432 [41]; 2002-573171 [61]; 2004-118988 [12]
DNC C2004-233217
TI New alpha- and beta-amino acid hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors in the treatment of AIDS.
DC B05
IN DECRESCENZO, G A; GETMAN, D P; MUELLER, R A; SUN, E T; TALLEY, J J; VAZQUEZ, M L
PA (SEAR) SEARLE & CO G D
CYC 1
PI US 2004171653 A1 20040902 (200463)F 44 A61K031-44 <--
ADT US 2004171653 A1 Div ex US 1992-968712 19921030, Cont of US 1996-709069 19960906, Cont of US 1999-345739 19990701, Cont of US 2000-731911 20001208, Cont of US 2002-138534 20020506, US 2003-689513 20031021
FDT US 2004171653 A1 Div ex US 5578606, Cont of US 6022872, Cont of US 6211176, Cont of US 6403585, Cont of US 6683648
PRAI US 1992-968712 19921030; US 1996-709069 19960906;
US 1999-345739 19990701; US 2000-731911 20001208;
US 2002-138534 20020506; US 2003-689513 20031021
IC ICM A61K031-44
ICS A61K031-40; C07C381-06
AB US2004171653 A UPAB: 20041001
NOVELTY - Alpha- and beta-amino acid hydroxyethylamino sulfonyl urea derivatives (I) are new.
DETAILED DESCRIPTION - Alpha- and beta-amino acid hydroxyethylamino sulfonyl urea derivatives of formula (I) are new.
R = H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, alkoxycarbonyl, aryloxycarbonyl, heteroaryloxyalkyl, aralkyloxycarbonyl,

(cyclo)alkylcarbonyl, cycloalkylalkoxycarbonyl, cycloalkylalkanoyl, alkanoyl, aralkanoyl, aroyl, aryloxycarbonyl, aryloxycarbonylalkyl, aryloxyalkanoyl, heterocyclylcarbonyl, heterocyclyloxycarbonyl, heterocyclylalkanoyl, heterocyclylalkoxycarbonyl, heteroaralkanoyl, heteroaralkoxycarbonyl, heteroaryloxycarbonyl, heteroaroyl, hydroxyalkyl, aminocarbonyl, aminoalkanoyl, and mono- and di-substituted aminocarbonyl and mono- and di-substituted aminoalkanoyl radicals (the substituents are selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, heterocycloalkyalkyl radicals, or when the aminoalkanoyl radical is disubstituted, the substituents along with the nitrogen atom to which they are attached form a heterocycloalkyl or heteroaryl radical);

R' = H, R3 or R3SO2;

N(R)R' = heterocycloalkyl or heteroaryl radicals;

R1 = -CH2SO2NH2, -CH2CO2CH3, -CO2CH3, -CONH2, -CH2C(O)NHCH3, -C(CH3)2(SH), -C(CH3)2(SCH3), -C(CH3)2(S(O)CH3), -C(CH3)2(S(O)2CH3), alkyl, haloalkyl, alkenyl, alkynyl and cycloalkyl radicals and amino acid side chains selected from asparagine, S-methyl cysteine and methionine and its sulfoxide (SO) and sulfone (SO2) derivatives, isoleucine, allo-isoleucine, alanine, leucine, tert-leucine, phenylalanine, ornithine, histidine, norleucine, glutamine, threonine, glycine, allo-threonine, serine, O-methyl serine, aspartic acid, beta-cyanoalanine and valine side chains;

R1' and R1'' = H or R1;

CR1'+CR1 or CR1+CR1'' = cycloalkyl radical;

R2 = alkyl, aryl, cycloalkyl, cycloalkylalkyl or aralkyl (optionally substituted by alkyl and halo radicals, -NO2, -CN, -CF3, -OR9 or -SR9);

R9 = H, alkyl or halo;

R3 = alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heteroaryl, heterocycloalkylalkyl, aryl, aralkyl, heteroaralkyl, aminoalkyl, and mono- and disubstituted aminoalkyl radicals (the substituents are selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, heterocycloalkylalkyl radicals or in the case of a disubstituted aminoalkyl radical, the substituents along with the nitrogen atom to which they are attached form heterocycloalkyl or heteroaryl), and thioalkyl, alkylthioalkyl and arylthioalkyl and their sulfone and sulfoxide derivatives;

R4, = H or R3;

R6 = H or alkyl;

R7 and R7' = H, R3, amino acid side chains selected from valine, isoleucine, glycine, alanine, allo-isoleucine, asparagines, leucine, glutamine or tert-butylglycine, -C(O)R16, -CO2R16, -SO2R16, -SR16, -CONR16R17, -CF3 or -NR16R17;

CR7R7' = cycloalkyl;

R8 = cyano, hydroxyl, alkyl, alkoxy, cycloalkyl, aryl, aralkyl, heterocycloalkyl, heteroaryl, C(O)R16, CO2R16, SO2R16, SR16, CONR16R17, CF3 or NR16R17;

R15, R16 and R17 = H or R3;

NR16R17 = heterocycloalkyl or heteroaryl;

x = 1 or 2;

n = 0 - 6;

t = 0 - 2; and

Y = O, S or NR15.

An INDEPENDENT CLAIM is included for a sulfonyl urea derivative of formula (II).

P1 = H, alkoxycarbonyl, aralkoxycarbonyl, alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkoxycarbonyl, cycloalkylalkanoyl, alkanoyl, aralkanoyl, aroyl, aryloxycarbonyl, aryloxycarbonylalkyl, aryloxyalkanoyl, heterocyclylcarbonyl, heterocyclyloxycarbonyl, heterocyclylalkanoyl, heterocyclylalkoxycarbonyl, heteroaralkanoyl, heteroaralkoxycarbonyl, heteroaryloxy-carbonyl, heteroaroyl, alkyl, alkenyl, cycloalkyl, aryl, aralkyl, aryloxyalkyl, heteroaryloxyalkyl, hydroxyalkyl, aminocarbonyl, aminoalkanoyl, and mono- and disubstituted aminocarbonyl and mono- and disubstituted aminoalkanoyl radicals, (the substituents are selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, heterocycloalkyalkyl radicals, or when aminoalkanoyl radical is disubstituted, the substituents along with the nitrogen atom to which they are attached form a heterocycloalkyl or heteroaryl radical);

P2 = H or R3;

NP1P2 = heterocycloalkyl or heteroaryl;

R8' = cyano, hydroxyl, alkyl, alkoxy, cycloalkyl, aryl, aralkyl, heterocycloalkyl and heteroaryl radicals and radicals represented by C(O)R16, CO2R16, SO2R16, SR16, CONR16R17, -CF3 and NR16R17.

ACTIVITY - Virucide.

MECHANISM OF ACTION - HIV Protease inhibitor; Retroviral protease inhibitor.

USE - For treating retroviral infection e.g. HIV infection and AIDS (claimed).

ADVANTAGE - The compounds are potent retroviral protease inhibitors.

Dwg.0/0

FS CPI

FA AB; GI; DCN

MC CPI: B06-H; B07-H; B10-A08; B14-A02B1; B14-D07C; B14-G01B